CA-AFFINITY
16.6.2022 13:02:11 CEST | Business Wire | Press release
Affinity — the relationship intelligence platform for dealmakers— today launched The Relationship Intelligence Benchmark Report: Unicorn Edition , which shares industry trends and analyzes over 390 unicorns in Europe and the United Kingdom with a deep dive into relationship intelligence and deal flows of the firms that invest in them.
Integrated data from the Affinity and Dealroom.co’s intelligence platforms found Europe has a unicorn growth rate more than twice that of the US and is home to 65 “unicorn cities.” These unicorn cities consist of London, Berlin, Paris, Stockholm, and Amsterdam, with more than half of all European unicorns located in the UK and Germany. Recognizing the growth internationally, U.S. investors have flocked to join and now account for 35% of all funding in Europe. This flood of investment has also increased unicorn valuations which are up by 305% in the last five years.
“The past decade has seen an exponential increase in the volume and diversity of new capital investing in startups - and is now entering turbulent economic times,” said Ray Zhou, co-CEO and co-founder at Affinity. “Our report highlights how Europe has adapted and grown, despite the effects of the pandemic, and shows how relationship intelligence plays a role in these major industry trends.”
As expected, many firms experienced a period of “bounce back” from 2020. In 2021, European unicorns raised over $45B, twice the amount raised in 2020. However, these unicorns only account for 14% of new unicorns globally. This means the competition among VC’s is significant as they try to time the right investment. Index Ventures is a single venture responsible for backing 10 European decacorns by itself. The combination of high valuations and less late-stage funding rounds requires VC’s to capitalize on their networks, warm introductions, and outreach. But as these firms and startups face uncertain economic conditions, it is important to understand the drivers for the previous success and how investors identify the next generation of high-growth startups in Europe.
Other key takeaways from the report include:
- Unicorns are roaming : Europe produced 5 times more unicorns in 2021 than in 2020.
- Germany is now a hotspot : German funding of unicorns grew over 300% in the last 5 years. Together with the UK, they have funded 2/3 of all Europe-based unicorns.
- Decacorns are on the rise : Over the past five years, this percentage of multibillion-dollar unicorns has risen by a staggering 560%. The total value of decacorns in 2021 was $777.4B; to date in 2022 is at $718.3B, guaranteeing it will exceed 2021’s numbers.
- The rebound is over : While firms saw an increase in deals, meetings and email volume in 2021, the beginning of 2022 tells a different story. In the first quarter of 2022, firms experienced 27% less meetings and deals, likely due to the inflation in Europe and predictions of an impending recession.
Read the full report here and then watch Affinity’s webinar “European Unicorn Trends: How to Make Unicorn Hunting More Predictable ,” which brings industry experts together to discuss the trends impacting dealmakers in this report as well as the role relationship intelligence plays in the evolving market landscape.
About Affinity
Affinity is a relationship intelligence platform that empowers dealmakers in relationship-driven industries to find, manage and close more deals. With the most automated relationship intelligence insights and technology, Affinity enables leaders to drive deals, free themselves from data drudgery and ensure their teams can take action with confidence, knowing the context and history of every relationship. The Affinity platform, including Affinity CRM, is used by over 2,000 relationship-driven organizations worldwide. Founded in 2014, Affinity is headquartered in San Francisco and backed by leading investors, including Menlo Ventures, Advance Venture Partners, 8VC and MassMutual Ventures.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220616005351/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
